Combination of Platelets Rich Plasma and Hyaluronic is an Effective Tool for Treatment of Knee Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-21

Study Completion Date

2025-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine the effects of HA, PRP and the combination of HA and PRP in reducing pain and improving functional disability in patients with knee osteoarthritis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study of Pain Reduction by Peri-arthroscopic PRP Application in Knee Degeneration

NCT02189408

Knee Osteoarthritis Cartilage Damage Meniscal Tear

COMPLETED PHASE4

Intraosseous With Intra-articular Injection of Platelet Rich Plasma in Treatment of Knee Osteoarthritis

NCT03329235

Osteoarthritis, Knee

COMPLETED EARLY_PHASE1

Effects of Steroid, Dextrose Prolotherapy, and Platelet-Rich Plasma Injections in Knee Joint OA Patients

NCT07243392

Knee Osteoarthritis

NOT_YET_RECRUITING NA

Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis

NCT04006314

Knee Osteoarthritis

UNKNOWN NA

The Synergistic Effects of Intra-articular Hyaluronic Acid and Platelet-rich Plasma Injections on Knee Osteoarthritis

NCT04443166

Osteoarthritis Knees Both

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To determine the effects of combination of platelet rich plasma (PRP) and hyaluronic acid and the PRP or HA alone in reducing pain and increasing range of motion among individuals with knee osteoarthritis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthristis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants were randomly divided into three groups. Twenty cases (Group A) were injected with HA, 20 (Group B) had PRP, and the remaining 20 (Group C) received a combination of HA and PRP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Single blinded study, only the assessor was kept blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Hyaluronic acid

Group Type EXPERIMENTAL

Hyaluronic Acid (HA)

Intervention Type DRUG

Hyaluronic Acid

Group B

platelet rich plasma

Group Type ACTIVE_COMPARATOR

Platelet Rich Plasma

Intervention Type DRUG

Platelet rich plasma

Group C

Hyaluronic acid and platelet rich plasma

Group Type OTHER

Hyaluronic Acid (HA) and Platelet rich plasma

Intervention Type DRUG

Hyaluronic Acid and Platelet rich plasma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyaluronic Acid (HA)

Hyaluronic Acid

Intervention Type DRUG

Platelet Rich Plasma

Platelet rich plasma

Intervention Type DRUG

Hyaluronic Acid (HA) and Platelet rich plasma

Hyaluronic Acid and Platelet rich plasma

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* grade II-III according to the Kellgren-Lawrence classification),
* pain or functional limitations in patients' activity of daily living before the treatment,
* age between 40 and 70 years of age, and the absence of clinical or imaging signs of articular instability.

Exclusion Criteria

* includes known hypersensitivity to hyaluronic acid,
* pregnancy and lactation, a BMI greater than 40 kg/m2,
* chronic administration of anticoagulant drugs or a history of coagulopathies,
* neoplastic lesions, and knee or kidney failures

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No